Colistin and polymyxin B: A re-emergence

@inproceedings{Gupta2009ColistinAP,
  title={Colistin and polymyxin B: A re-emergence},
  author={Sachin Gupta and Deepika Govil and Prem N. Kakar and O. Kameswara Satya Prakash and Deep Shikha Arora and Shibani Das and Pradeep K. Govil and Ashima Malhotra},
  booktitle={Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine},
  year={2009}
}
One of the greatest achievements of modern medicine is the development of antibiotics against life-threatening infections, but the emergence of multidrug-resistant (MDR) gram negative bacteria has drastically narrowed down the therapeutic options against them. This limitation has led clinicians to reappraise the clinical application of polymyxins, an old class of cationic, cyclic polypeptide antibiotics. Polymyxins are active against selected gram-negative bacteria, including the Acinetobacter… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 22 CITATIONS

Rat models of colistin nephrotoxicity: previous experimental researches and future perspectives

  • European Journal of Clinical Microbiology & Infectious Diseases
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 38 REFERENCES

Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic.

  • Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • 2005
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Parenteral (package insert). Mosman, NSW, Australia: Link Medical Products

M Coly-Mycin
  • Pty Ltd;
  • 2006
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…